Appendix 17b: combination therapy forest plots

The forest plots for combined psychological-pharmacological treatments are referenced 'Combo xx.xx' in the evidence profiles (appendix 18) and summary evidence profiles in the chapters.

Combo 01.01 aggression measures	.2
Combo 02.01 anger measures	
Combo 03.01 anxiety measures	.2
Combo 04.01 depression measures (self-rated)	.3
Combo 04.02 depression measures (clinician-rated)	
Combo 05.01 global functioning measures	.3
Combo 06.01 quality of life measures	.4
Combo 07.01 self-harm/suicidality	.4
Combo 08.01 service use measures	
Combo 09.01 antidepressants: leaving treatment early for any reason	.5
Combo 09.02 antipsychotics: leaving treatment early for any reason	.5
Combo 10.01 antidepressants: leaving treatment early due to side-effects	.6
Combo 10.02 antipsychotics: leaving treatment early due to side-effects	.6
Combo 11.01 antidepressants: number of participants reporting side-effects	.6
Combo 11.02 antipsychotics: number of participants reporting side-effects	.7
Combo 12.01 antipsychotics: weight change	.7
Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures	.7
Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures	.8
Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures	.8
Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures	
Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures	
Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability1	
Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures1	
Combo 15.02 fluoxetine + DBT versus placebo: quality of life measures1	
Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability1	
Combo 16.01 olanzapine + DBT versus placebo: efficacy measures1	
Combo 16.02 olanzapine + DBT versus placebo: service use measures1	
Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures1	
Combo 16.04 olanzapine + DBT versus placebo: side-effects1	14

DRAFT FOR CONSULTATION Combo 01.01 aggression measures

 Review:
 BPD combination pharmacology-psychology


 Comparison:
 01 Aggression measures

 Outcome:
 01 Clinician-rated measures

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)		S	SMD (fixed) 95% CI)	SMD (fixed) 95% Cl
01 Fluoxetine + DBT vs placet	oo + DBT: OA	AS-M - aggression subsca	ale (12 weeks)						
Simpson 2004 Flx+DBT	9	2.56(3.81)	11	7.45(10.05)			-		-0.59 [-1.50, 0.31]
Subtotal (95% CI)	9		11				-		-0.59 [-1.50, 0.31]
Test for heterogeneity: not app	licable						1		
Test for overall effect: Z = 1.28									
					-10	-5	0	5	10

Favours treatment Favours control

Combo 02.01 anger measures



Favours treatment Favours control


Combo 03.01 anxiety measures

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Fluoxetine + IPT vs fluoxetin	e: HARS (2	4 weeks)				
Bellino2004 Flx+IPT	16	11.00(4.40)	16	10.20(3.10)		0.20 [-0.49, 0.90]
Subtotal (95% CI)	16		16		◆	0.20 [-0.49, 0.90]
Test for heterogeneity: not appli Test for overall effect: Z = 0.58						
02 Fluoxetine + IPT vs fluoxetin	e + CT: HA	RS (24 weeks)				
Bellino2007 Flx+IPT	14	13.70(2.80)	12	12.50(1.10)		0.53 [-0.26, 1.32]
Subtotal (95% CI)	14		12		•	0.53 [-0.26, 1.32]
est for heterogeneity: not appli est for overall effect: Z = 1.32						
)3 Olanzapine + DBT vs placeb	o + DBT: H	IARS (12 weeks)				
Soler2005 Olz+DBT	30	18.43(5.94)	30	19.93(6.87)	=	-0.23 [-0.74, 0.28]
Subtotal (95% CI)	30		30		•	-0.23 [-0.74, 0.28]
Test for heterogeneity: not appli	cable					
est for overall effect: Z = 0.89	(P = 0.37)					
04 Fluoxetine + DBT vs placebo	+ DBT: S1	TAI (12 weeks)				
Simpson 2004 Flx+DBT	9	101.33(38.06)	11	96.18(28.83)		0.15 [-0.73, 1.03]
Subtotal (95% CI)	9		11		•	0.15 [-0.73, 1.03]
Test for heterogeneity: not appli	cable				[
Test for overall effect: Z = 0.33	(P = 0.74)					


Combo 04.01 depression measures (self-rated)

Study		Treatment		Control			MD (fixed)			SMD (fixed)	
or sub-category	Ν	Mean (SD)	N	Mean (SD)			95% CI			95% CI	
01 Fluoxetine + DPT vs plac	ebo + DBT: BI	DI (12 weeks)									
Simpson 2004 Flx+DBT	9	25.00(18.04)	11	13.91(9.54)			-			0.76 [-0.16, 1.68]	
Subtotal (95% CI)	9		11							0.76 [-0.16, 1.68]	
Test for heterogeneity: not a	pplicable						1				
Test for overall effect: Z = 1.	62 (P = 0.11)										
02 Fluoxetine + IPT vs fluoxe	etine + CT: HA	RS (24 weeks)									
Bellino2007 Flx+IPT	14	15.70(4.50)	12	14.70(1.90)			-			0.27 [-0.50, 1.05]	
Subtotal (95% CI)	14		12				-			0.27 [-0.50, 1.05]	
Test for heterogeneity: not a	pplicable						ľ				
Test for overall effect: Z = 0.	69 (P = 0.49)										
					10	+	-	÷	10		
					-10	-5	U	5	10		
					Favou	rs treatme	nt Favo	ours contro	bl		

Combo 04.02 depression measures (clinician-rated)



Combo 05.01 global functioning measures



Combo 06.01 quality of life measures

Review:	BPD combination pharmacology-psychology
Comparison:	06 Quality of life measures
Outcome:	01 Fluoxetine + IPT vs fluoxetine or fluoxetine + CT

Study or sub-category	Ν	Treatment Mean (SD)	Ν	Control Mean (SD)		SM	D (random) 95% CI	SMD (random) 95% Cl
01 SAT-P physical (24 weeks)								
Bellino2004 Flx+IPT	16	62.80(11.90)	16	59.50(16.70)				0.22 [-0.47, 0.92]
Bellino2007 Flx+IPT	14	54.40(14.90)	12	60.00(7.70)		_	━┼	-0.45 [-1.23, 0.34]
Subtotal (95% CI)	30		28				◆	-0.09 [-0.74, 0.57]
Test for heterogeneity: $Chi^2 = 1$ Test for overall effect: $Z = 0.26$		P = 0.21), l ² = 36.2%						
02 SAT-P psychological (24 we	eeks)							
Bellino2004 Flx+IPT	16	57.20(14.70)	16	69.00(11.70)			-	-0.87 [-1.59, -0.14]
Bellino2007 Flx+IPT	14	56.10(15.40)	12	63.70(14.20)		_	■┼	-0.50 [-1.28, 0.29]
Subtotal (95% CI)	30		28			•		-0.69 [-1.23, -0.16]
Test for heterogeneity: $Chi^2 = C$ Test for overall effect: $Z = 2.55$		P = 0.50), l ² = 0%					-	
03 SAT-P sleep, food, free time	e (24 weeks))						
Bellino2004 Flx+IPT	16	64.50(14.90)	16	56.40(20.70)			+	0.44 [-0.26, 1.14]
Bellino2007 Flx+IPT	14	53.10(8.80)	12	53.30(13.70)			_ 	-0.02 [-0.79, 0.75]
Subtotal (95% CI)	30		28				+	0.23 [-0.29, 0.75]
Test for heterogeneity: $Chi^2 = 0$ Test for overall effect: $Z = 0.87$		P = 0.39), l ² = 0%						
04 SAT-P social functioning (24	4 weeks)							
Bellino2004 Flx+IPT	16	51.70(10.90)	16	68.50(12.50)		_	-	-1.40 [-2.18, -0.61]
Bellino2007 Flx+IPT	14	70.00(12.80)	12	55.00(14.80)			—	1.06 [0.22, 1.89]
Subtotal (95% CI)	30		28					-0.17 [-2.58, 2.23]
Test for heterogeneity: $Chi^2 = 1$ Test for overall effect: $Z = 0.14$		(P < 0.0001), I ² = 94.4%						
05 SAT-P work (24 weeks)								
Bellino2004 Flx+IPT	16	54.40(14.60)	16	56.00(31.20)				-0.06 [-0.76, 0.63]
Bellino2007 Flx+IPT	14	51.90(20.20)	12	39.20(10.20)			⊢ ∎−−	0.75 [-0.05, 1.55]
Subtotal (95% CI)	30		28					0.32 [-0.48, 1.11]
Test for heterogeneity: $Chi^2 = 2$ Test for overall effect: $Z = 0.78$		P = 0.13), l ² = 55.9%						
					-4	-2	0 2	4
					Favo	urs treatme	ent Favours co	ontrol


Combo 07.01 self-harm/suicidality

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% Cl
01 Fluoxetine + DBT vs placebo	+ DBT: 0\	vert aggression scale - sui	cidality subsc	ale (12 weeks)		
Simpson 2004 Flx+DBT	9	2.13(3.48)	11	1.00(1.18)		0.44 [-0.46, 1.33]
Subtotal (95% CI)	9		11		•	0.44 [-0.46, 1.33]
Test for heterogeneity: not appli						
Test for overall effect: Z = 0.96	(P = 0.34)					
02 Olanzapine + DBT vs placeb	o + DBT: S	elf-harm/suicide attempts	(12 weeks)			
Soler2005 Olz+DBT	30	1.23(2.87)	30	0.88(1.68)	—	0.15 [-0.36, 0.65]
Subtotal (95% CI)	30		30		•	0.15 [-0.36, 0.65]
Test for heterogeneity: not appli	cable					
Test for overall effect: Z = 0.57	P = 0.57)					
03 Fluoxetine + DBT vs placebo	+ DBT: O		f-injury subsc			
Simpson 2004 Flx+DBT	9	7.00(12.37)	11	6.55(12.64)	—	0.03 [-0.85, 0.92]
Subtotal (95% CI)	9		11		•	0.03 [-0.85, 0.92]
Test for heterogeneity: not appli						
Test for overall effect: Z = 0.08	P = 0.94					


Combo 08.01 service use measures

Outcome: 01 Olanzap		blacebo + DBT: Number o		ergency psychiatric servi	KS)			
Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)	W	/MD (fixed 95% CI	I)	WMD (fixed) 95% CI
Soler2005 Olz+DBT	30	0.07(0.27)	30	0.03(0.20)		-		0.04 [-0.08, 0.16]
Fotal (95% CI) Fest for heterogeneity: not a Fest for overall effect: Z = 0.			30					0.04 [-0.08, 0.16]

Combo 09.01 antidepressants: leaving treatment early for any reason



Combo 09.02 antipsychotics: leaving treatment early for any reason




Combo 10.01 antidepressants: leaving treatment early due to side-effects


Comparison: 10 Le	combination pharmacology-psycho eaving treatment early due to side-e ntidepressants (non-placebo compa	ffects		
Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% Cl	RD (fixed) 95% Cl
01 Fluoxetine + DBT v	s placebo + DBT			
Simpson 2004 Flx+DE	· · · · · · · · · · · · · · · · · · ·	0/13	<u> </u>	0.00 [-0.14, 0.14]
Subtotal (95% CI)	12	13	Т	0.00 [-0.14, 0.14]
Total events: 0 (Treatn	nent), 0 (Control)			
Test for heterogeneity:	not applicable			
Test for overall effect:	Z = 0.00 (P = 1.00)			
04 Fluoxetine + IPT vs	fluoxetine			
Bellino2004 Flx+IPT	0/19	0/20	<u> </u>	0.00 [-0.09, 0.09]
Subtotal (95% CI)	19	20	Т	0.00 [-0.09, 0.09]
Total events: 0 (Treatn	nent), 0 (Control)			
Test for heterogeneity:	not applicable			
Test for overall effect:	Z = 0.00 (P = 1.00)			
		+		4000
		-100	0 -500 0 500	1000

Favours treatment Favours control

Combo 10.02 antipsychotics: leaving treatment early due to side-effects




Combo 11.01 antidepressants: number of participants reporting side-effects



Combo 11.02 antipsychotics: number of participants reporting side-effects

Review: Comparison: Outcome:	11 Number of par	e pharmacology-psycholo rticipants reporting side s (non-placebo comparis	effects						
Study or sub-category	,	Treatment n/N	Control n/N			RD (fixed) 95% CI			RD (fixed) 95% Cl
03 Olanzapine	+ DBT vs placebo +	DBT							
Soler2005 Olz	+DBT	0/30	0/30			•			0.00 [-0.06, 0.06]
Subtotal (95%)	CI)	30	30			Т			0.00 [-0.06, 0.06]
Test for heterog	(Treatment), 0 (Cor geneity: not applical	ble							
Test for overall	effect: Z = 0.00 (P =	= 1.00)							
				-1000	-500	0	500	1000	
				Favo	urs treatme	ent Fav	ours cont	rol	

Combo 12.01 antipsychotics: weight change



Combo 13.01 fluoxetine + IPT versus fluoxetine: efficacy measures

Comparison:	BPD combination phan 13 Fluoxetine + IPT ve 01 Efficacy measures							
Study or sub-category	Ν	Treatment Mean (SD)	Ν	Control Mean (SD)		SMD (fixed) 95% CI		SMD (fixed) 95% Cl
01 Anxiety (Clinic	ian-rated: HARS) (24 v	/eeks)						
Bellino2004 Flx+	HPT 16	11.00(4.40)	16	10.20(3.10)				0.20 [-0.49, 0.90]
Subtotal (95% CI)	16		16					0.20 [-0.49, 0.90]
Test for heteroger	neity: not applicable					ſ		
Test for overall ef	fect: Z = 0.58 (P = 0.56	i)						
02 Depression (cl	inician-rated) HRSD (2	4 weeks)						
Bellino2004 Flx+			16	12.00(3.30)		-		-0.90 [-1.63, -0.16]
Subtotal (95% CI)	16		16			•		-0.90 [-1.63, -0.16]
Test for heteroge	neity: not applicable					•		
Test for overall ef	fect: Z = 2.40 (P = 0.02	:)						
							+ +	
					-10	-5 0	5 10	
					Favour	s treatment Favour	s control	

Combo 13.02 fluoxetine + IPT versus fluoxetine: quality of life measures

 Review:
 BPD combination pharmacology-psychology

 Comparison:
 13 Fluoxetine + IPT versus fluoxetine

 Outcome:
 02 QOL: Fluoxetine vs fluoxetine + IPT

Study or sub-category	Ν	Treatment Mean (SD)	N	Control Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 SAT-P physical (24 weeks)						
Bellino2004 Flx+IPT	16	62.80(11.90)	16	59.50(16.70)		0.22 [-0.47, 0.92]
ubtotal (95% CI)	16		16			0.22 [-0.47, 0.92]
est for heterogeneity: not appli est for overall effect: Z = 0.63 (
2 SAT-P psychological (24 wee	eks)					
Bellino2004 Flx+IPT	16	57.20(14.70)	16	69.00(11.70)	-	-0.87 [-1.59, -0.14]
ubtotal (95% CI)	16		16		T	-0.87 [-1.59, -0.14]
est for heterogeneity: not appli	icable					
est for overall effect: Z = 2.33 ((P = 0.02)					
3 SAT-P sleep, food, free time	(24 weeks)					
Bellino2004 Flx+IPT	16	64.50(14.90)	16	56.40(20.70)		0.44 [-0.26, 1.14]
ubtotal (95% CI)	16		16			0.44 [-0.26, 1.14]
est for heterogeneity: not appli						
est for overall effect: Z = 1.22 ((P = 0.22)					
4 SAT-P social functioning (24	weeks)					
Bellino2004 Flx+IPT	16	51.70(10.90)	16	68.50(12.50)		-1.40 [-2.18, -0.61]
ubtotal (95% CI)	16		16			-1.40 [-2.18, -0.61]
est for heterogeneity: not appli est for overall effect: Z = 3.49 (
5 SAT-P work (24 weeks)						
Bellino2004 Flx+IPT	16	54.40(14.60)	16	56.00(31.20)		-0.06 [-0.76, 0.63]
ubtotal (95% CI)	16	51.10(11.00)	16	55.00(51.20)	T	-0.06 [-0.76, 0.63]
est for heterogeneity: not appli			10			0.00 [0.00, 0.00]
est for overall effect: Z = 0.18 (
	(1 = 0.00)					
					-100 -50 0 50	
					Favours treatment Favours of	control

Combo 13.03 fluoxetine + IPT versus fluoxetine: acceptability and tolerability measures

	n/N	Control n/N	RD (fixed) 95% Cl	RD (fixed) 95% CI
1 Leaving treatment early for any	reason			
Bellino2004 Flx+IPT	4/20	3/19	•	0.04 [-0.20, 0.28]
Subtotal (95% CI)	20	19		0.04 [-0.20, 0.28]
Total events: 4 (Treatment), 3 (Co				
Test for heterogeneity: not applica				
Test for overall effect: Z = 0.34 (P	= 0.73)			
2 Leaving treatment early due to	side effects			
Bellino2004 Flx+IPT	0/19	0/20	<u> </u>	0.00 [-0.09, 0.09]
Subtotal (95% CI)	19	20	Т	0.00 [-0.09, 0.09]
Total events: 0 (Treatment), 0 (Co	ntrol)			
Test for heterogeneity: not applica	ble			
Test for overall effect: Z = 0.00 (P	= 1.00)			
3 Number of participants reportin	a side effects			
Bellino2004 Flx+IPT	0/19	0/20	• • • • • • • • • • • • • • • • • • •	0.00 [-0.09, 0.09]
Subtotal (95% CI)	19	20	Т	0.00 [-0.09, 0.09]
Total events: 0 (Treatment), 0 (Co	ntrol)			
Fest for heterogeneity: not applica	ble			
Test for overall effect: Z = 0.00 (P	= 1.00)			

Combo 14.01 fluoxetine + IPT versus fluoxetine + CT: efficacy measures

 Review:
 BPD combination pharmacology-psychology

 Comparison:
 14 Fluoxetine + IPT versus fluoxetine + CT


 Outcome:
 01 Efficacy measures

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)			ID (fixed) 95% CI			SMD (fixed) 95% Cl
01 Anxiety (Clinician-rated: H	HARS) (24 wee	ks)								
Bellino2007 Flx+IPT	14	13.70(2.80)	12	12.50(1.10)			-			0.53 [-0.26, 1.32]
Subtotal (95% CI)	14		12				•			0.53 [-0.26, 1.32]
Test for heterogeneity: not ap	pplicable									
Test for overall effect: Z = 1.3	32 (P = 0.19)									
02 Depression (clinician-rate	d) HRSD (24 v	veeks)								
Bellino2007 Flx+IPT	14	14.10(5.50)	12	13.70(5.70)			-			0.07 [-0.70, 0.84]
Subtotal (95% CI)	14		12				•			0.07 [-0.70, 0.84]
Test for heterogeneity: not ap	pplicable						[
Test for overall effect: Z = 0.1	18 (P = 0.86)									
03 Depression (self-rated) BI	DI (24 weeks)									
Bellino2007 Flx+IPT	14	15.70(4.50)	12	14.70(1.90)			-			0.27 [-0.50, 1.05]
Subtotal (95% CI)	14		12				٠			0.27 [-0.50, 1.05]
Test for heterogeneity: not ap	pplicable						ſ			
Test for overall effect: Z = 0.6	69 (P = 0.49)									
					-10	-5	0	5	10	
					Favour	s treatmer	nt Favo	ours contro	I	

Combo 14.02 fluoxetine + IPT versus fluoxetine + CT: quality of life measures

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)	SMD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 SAT-P physical (24 weeks)						
Bellino2007 Flx+IPT	14	54.40(14.90)	12	60.00(7.70)		-0.45 [-1.23, 0.34]
Subtotal (95% CI)	14		12			-0.45 [-1.23, 0.34]
est for heterogeneity: not app est for overall effect: Z = 1.12						
2 SAT-P psychological (24 we	eks)					
Bellino2007 Flx+IPT	14	56.10(15.40)	12	63.70(14.20)		-0.50 [-1.28, 0.29]
Subtotal (95% CI)	14		12			-0.50 [-1.28, 0.29]
Test for heterogeneity: not app Test for overall effect: Z = 1.24						
03 SAT-P sleep, food, free time	e (24 weeks)					
Bellino2007 Flx+IPT	14	53.10(8.80)	12	53.30(13.70)		-0.02 [-0.79, 0.75]
Subtotal (95% CI)	14		12			-0.02 [-0.79, 0.75]
Test for heterogeneity: not app						
est for overall effect: Z = 0.04	(P = 0.97)					
04 SAT-P social functioning (24	1 weeks)					
Bellino2007 Flx+IPT	14	70.00(12.80)	12	55.00(14.80)		1.06 [0.22, 1.89]
Subtotal (95% CI)	14		12			1.06 [0.22, 1.89]
Fest for heterogeneity: not app Fest for overall effect: Z = 2.49						
05 SAT-P work (24 weeks)						
Bellino2007 Flx+IPT	14	51.90(20.20)	12	39.20(10.20)		0.75 [-0.05, 1.55]
Subtotal (95% CI)	14		12		Т	0.75 [-0.05, 1.55]
Test for heterogeneity: not app						
Test for overall effect: Z = 1.83	(P = 0.07)					

Combo 14.03 fluoxetine + IPT versus fluoxetine + CT: acceptability and tolerability




Combo 15.01 fluoxetine + DBT versus placebo: efficacy measures

Review:BPD combinationComparison:15 Fluoxetine + DOutcome:01 Efficacy meas	BT versu	cology-psychology us placebo					
Study or sub-category	N	Treatment Mean (SD)	N	Control Mean (SD)	s	MD (fixed) 95% Cl	SMD (fixed) 95% Cl
01 Aggression (clinician-rated: OA							
Simpson 2004 Flx+DBT Subtotal (95% CI)	9 9	2.56(3.81)	11 11	7.45(10.05)			-0.59 [-1.50, 0.31] -0.59 [-1.50, 0.31]
Test for heterogeneity: not applical							0.00 [1.00, 0.01]
Test for overall effect: Z = 1.28 (P	= 0.20)						
02 Anger (STAXI 12 weeks)							
Simpson 2004 Flx+DBT Subtotal (95% CI)	9 9	20.56(12.19)	11 11	27.64(12.36)			-0.55 [-1.45, 0.35] -0.55 [-1.45, 0.35]
Test for heterogeneity: not applical							0.00 [1.10, 0.00]
Test for overall effect: Z = 1.20 (P							
03 Anxiety (Clinician-rated: STAI 1				06 10/00 000		L	
Simpson 2004 Flx+DBT Subtotal (95% CI)	9 9	101.33(38.06)	11 11	96.18(28.83)			0.15 [-0.73, 1.03] 0.15 [-0.73, 1.03]
Test for heterogeneity: not applical						Ť	0.13 [0.757 1.05]
Test for overall effect: Z = 0.33 (P	= 0.74)						
04 Depression (clinician-rated HRS			2.0	15 00/5 41)		1	
Soler2005 Olz+DBT Subtotal (95% CI)	30 30	13.71(5.46)	30 30	15.80(6.41)			-0.35 [-0.86, 0.16] -0.35 [-0.86, 0.16]
Test for heterogeneity: not applical			50			1	0.00 [0.00, 0.10]
Test for overall effect: Z = 1.33 (P	= 0.18)						
05 Depression (self-rated BDI 12 v Simpson 2004 Flx+DBT	veeks) 9	25.00(18.04)	11	13.91(9.54)			0.76 [-0.16, 1.68]
Subtotal (95% CI)	9	25.00(18.04)	11	13.91(9.34)		-	0.76 [-0.16, 1.68]
Test for heterogeneity: not application						-	
Test for overall effect: Z = 1.62 (P	= 0.11)						
06 Global functioning (GAF 12 wee Simpson 2004 Flx+DBT	e <mark>ks)</mark> 9	59.92(13.15)	11	59.30(7.17)		1	0.06 [-0.82, 0.94]
Subtotal (95% CI)	9	59.92(15.15)	11	59.30(7.17)			0.06 [-0.82, 0.94]
Test for heterogeneity: not application						T	
Test for overall effect: Z = 0.13 (P	= 0.90)						
07 Suicidality: Overt aggression so	ale - suic 9	cidality subscale (12 weeks) 2.13(3.48)	11	1.00(1.18)			0 44 [0 46 1 22]
Simpson 2004 Flx+DBT Subtotal (95% CI)	9	2.13(3.48)	11	1.00(1.18)		-	0.44 [-0.46, 1.33] 0.44 [-0.46, 1.33]
Test for heterogeneity: not applical							0.11 (0.10, 1.00)
Test for overall effect: Z = 0.96 (P	= 0.34)						
08 Self-injury: Overt aggression sc						1	
Simpson 2004 Flx+DBT Subtotal (95% CI)	9 9	7.00(12.37)	11 11	6.55(12.64)			0.03 [-0.85, 0.92] 0.03 [-0.85, 0.92]
Test for heterogeneity: not applical						Ť	0.03 [0.03, 0.92]
Test for overall effect: Z = 0.08 (P							
					-10 -5	0 5	10
					Favours treatm	ent Favours con	trol

Combo 15.02 fluoxetine + DBT versus placebo: quality of life measures

Study or sub-category	Ν	Treatment Mean (SD)	Ν	Control Mean (SD)	SMD (95%	(fixed) % Cl	SMD (fixed) 95% CI
01 SAT-P physical (24 weeks) Subtotal (95% CI) Test for heterogeneity: not app Test for overall effect: not app	0 blicable		0				Not estimable
02 SAT-P psychological (24 w Subtotal (95% CI) Test for heterogeneity: not app Test for overall effect: not app	0 blicable		0				Not estimable
03 SAT-P sleep, food, free tim Subtotal (95% Cl) Test for heterogeneity: not app Test for overall effect: not app	0 blicable		0				Not estimable
04 SAT-P social functioning (2 Subtotal (95% CI) Test for heterogeneity: not app Test for overall effect: not app	0 blicable		0				Not estimable
05 SAT-P work (24 weeks) Subtotal (95% CI) Test for heterogeneity: not app Test for overall effect: not app			0				Not estimable


Combo 15.03 fluoxetine + DBT versus placebo: acceptability and tolerability



Combo 16.01 olanzapine + DBT versus placebo: efficacy measures

Study or sub-category	N	Treatment Mean (SD)	Ν	Control Mean (SD)	SMD (fixed) 95% CI	SMD (fixed) 95% CI
01 Anxiety (Clinician-rated	HARS 12 week	s)				
Soler2005 Olz+DBT	30	18.43(5.94)	30	19.93(6.87)		-0.23 [-0.74, 0.28]
Subtotal (95% CI)	30		30		•	-0.23 [-0.74, 0.28]
Test for heterogeneity: not	applicable					
Test for overall effect: Z = 0	0.89 (P = 0.37)					
02 Depression (clinician-ra	ed HRSD 12 we	eeks)				
Soler2005 Olz+DBT	30	13.71(5.46)	30	15.80(6.41)		-0.35 [-0.86, 0.16]
Subtotal (95% CI)	30		30		•	-0.35 [-0.86, 0.16]
Test for heterogeneity: not	applicable					
Test for overall effect: Z = 7	.33 (P = 0.18)					
03 Self-harm/suicide attem						
Soler2005 Olz+DBT	30	1.23(2.87)	30	0.88(1.68)	—	0.15 [-0.36, 0.65]
Subtotal (95% CI)	30		30		•	0.15 [-0.36, 0.65]
Test for heterogeneity: not						
Test for overall effect: Z = 0).57 (P = 0.57)					

Combo 16.02 olanzapine + DBT versus placebo: service use measures



Combo 16.03 olanzapine + DBT versus placebo: acceptability and tolerability measures

 Review:
 BPD combination pharmacology-psychology

 Comparison:
 16 Olanzapine + DBT versus placebo

 Outcome:
 03 Tolerability and acceptability data

Study or sub-category	Treatment n/N	Control n/N	RD (fixed) 95% Cl	RD (fixed) 95% Cl
01 Leaving treatment early for ar	ny reason			
Soler2005 Olz+DBT	8/30	10/30	<u> </u>	-0.07 [-0.30, 0.16]
Subtotal (95% CI)	30	30	Т	-0.07 [-0.30, 0.16]
Total events: 8 (Treatment), 10 (Control)			
Test for heterogeneity: not applic	cable			
Test for overall effect: $Z = 0.56$ (F	P = 0.57)			
02 Leaving treatment early due to	o side effects DATA UNC	LEAR		
Subtotal (95% CI)	0	0		Not estimable
Total events: 0 (Treatment), 0 (C	Control)			
Test for heterogeneity: not applic	cable			
Test for overall effect: not application	able			
03 Number of participants report	ing side effects			
Soler2005 Olz+DBT	0/30	0/30	<u> </u>	0.00 [-0.06, 0.06]
Subtotal (95% CI)	30	30	Т	0.00 [-0.06, 0.06]
Total events: 0 (Treatment), 0 (C	Control)			
Test for heterogeneity: not applic	,			
Test for overall effect: $Z = 0.00$ (F	P = 1.00)			
		-100	0 -500 0 500	1000
		F	avours treatment Favours contr	ol

Borderline personality disorder: full guideline appendix 17B DRAFT (June 2008)

Combo 16.04 olanzapine + DBT versus placebo: side-effects

